东方田鼠非酒精性脂肪肝模型的建立及研究
|
摘要
目的：
非酒精性脂肪肝(nonalcoholic fatty liver disease,NAFLD)发病率逐年增高,且有进展到肝纤维化肝硬化的趋势,目前其确切的发病机制尚不清楚。我们在以往的实验中发现东方田鼠有易发脂肪肝的倾向,因此建立东方田鼠非酒精性脂肪肝模型,利用SMART (Switching Mechanism at 5'end of RNA Transcript, RNA5'端转录机制)技术构建了东方田鼠肝脏cDNA (complementary DNA,互补DNA)质粒文库,在此基础上筛选与东方田鼠脂肪肝发病相关的基因,并获得其全长序列,为进一步研究非酒精脂肪肝发病机制奠定基础。
方法：
选取105只6周龄洞庭湖种群雄性东方田鼠,随机分成三组,每组35只,分别为对照组、模型组1和模型组2,各组分别饲喂高纤维料(在大小鼠基础料的基础上加粗纤维,使粗纤维含量为10%,粗脂肪含量为3%)、高脂料(在大小鼠基础料的基础上加5%猪油、0.5%胆固醇和0.1%胆盐)、大小鼠基础料。各组分别于造模开始后第2、4、6、8、12周处死,称量体重及肝重,计算肝指数,采血检测东方田鼠血清丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、甘油三酯(TG)、总胆固醇(TC)、碱性磷酸酶(ALP)、游离脂肪酸(FFA)、血糖(GLU)、r-谷氨酰转移酶(r-GGT)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)和胆碱酯酶(CHE),并取肝脏HE染色后做病理学观察。通过文献确定,可能与非酒精性脂肪肝相关的基因,参照NCBI中大小鼠基因cDNA序列的保守区设计其特异性引物,进行实时荧光定量PCR检测,比较基因动态表达水平。
选取12月龄洞庭湖种群东方田鼠4只,取肝脏组织,提取总RNA,用SMART技术构建东方田鼠肝脏cDNA质粒文库,测定文库滴度和容量,并随机挑选单个菌落测序,计算全长基因的比率
根据实时荧光定量PCR结果确定目的基因,通过PCR方法筛选cDNA质粒文库,获得目的菌落,用pBluescriptⅡSK通用引物M13R测序,获得基因的全长序列,并进行序列分析比较。
结果：
模型组1东方田鼠肝细胞均呈现弥漫性脂肪变性,模型组2东方田鼠肝细胞脂肪变性较轻,对照组东方田鼠肝脏基本正常。
与对照组相比,模型组1肝重和肝指数都明显升高(P<0.05),血清ALT、AST、TC、FFA、r-GGT、LDL、CHE和GLU都明显升高(P<0.05),HDL和TG均明显降低(P<0.05),ALP无明显差异(P>0.05)；对8个基因进行了实时荧光定量PCR结果显示肝组织中的CYP2E1(细胞色素P4502E1)、ECHS1(烯酰辅酶A水合酶短链1)、CYP2D5(细胞色素P4502D5)、CYP2a3a(细胞色素P4502a3a)和PGC-1(过氧化物酶体增殖物激活受体辅激活因子1)这5基因表达上调(P<0.05),SC4MOL(固醇甲基氧化酶)、Adipor(脂联素受体)和AMPK-1(腺苷酸活化激酶-1)这3个基因表达下调(P<0.05)。
与对照组相比,模型组2肝重和肝指数明显升高(P<0.05),血清FFA、LDL、CHE显著升高(P<0.05),HDL明显降低(P<0.05),其余指标与对照组相比无显著差异；实时荧光定量PCR结果显示所测基因未有明显改变(P>0.05)。
利用SMART技术构建了东方田鼠肝脏cDNA质粒文库,该cDNA文库滴度为1076 pfu/μL,重组率约94%,库容量达1.08×106。测定了22个克隆序列经BLAST分析,与GenBank中大鼠、小鼠、田鼠以及人类已知功能蛋白具有75%以上的同源性,基因完整性比率为77.3%。
克隆了CYP2E1、CYP2D5、ECHS1三个基因,并获得了它们的全长cDNA序列。CYP2E1基因cDNA全长为1685bp,有1482bp的完整开放阅读框,编码494个氨基酸：CYP2D5基因cDNA全长为1690bp,有1514bp的完整开放阅读框,编码504个氨基酸；ECHS1基因cDNA全长为1013bp,有873bp的完整开放阅读框,编码290个氨基酸。这三个基因的核酸序列及其推测的氨基酸序列与人、大小鼠序列高度同源。在GenBank中注册号分别为GQ507485、GQ507486、GQ845171。
Objective:
The incidence of Non-alcoholic fatty liver (nonalcoholic fatty liver disease, NAFLD) increased year by year, and the disease can progress to liver fibrosis and cirrhosis, but its precise mechanism is currently unclear. Our early experiment showed that Microtus fortis is prone to fatty liver, therefore, the purpose of this study is to establish a Non-alcoholic fatty liver model of Microtus fortis, and to study the pathogenesis of Non-alcoholic fatty liver disease in the model of Microtus fortis.
Methods:
We selected 105 male Microtus fortis in Dongting Lake which are 6-week-old, and randomly divided them into three groups.The three groups were fed the high-fat ingredients (plus 5% lard,0.5% cholesterol and 0.1% bile salt into based on the standard diet for rats and mice, model 1 group), the standard diet (model 2 group), the high-fiber material (the final concentration of Bold fiber was 10%, crude fat was 3% on the basis of the standard diet for rats and mice, control group) respectively.7 voles of each group were sacrificed at the beginning of the study time of 2,4,6,8,12week. During the process of our study we had observed the general situation and changes in liver index of Microtus fortis. ALT, AST, TG, TC, ALP, FFA, r-GT, HDL, LDL, CHE, GLU values were measured by biochemistry analyzer. The histological changes of all voles'livers were observed using light microscopy. Genes which should be possible related to non-alcoholic fatty liver were selectecd. The cDNA-specific primers were designed in the conserved region according to the sequences of mice and rats from the NCBI. Then real-time PCR was done to obtain the gene expression levels of the livers.
We selected four Microtus fortis in Dongting Lake which are 12 months of age, after we sacrificed them whichever liver were obtained to extracte total RNA, then The plasmid cDNA library from liver of Microtus fortis was constructed by using SMART technology. The titers and capacity of this cDNA library were determined. Randomly selected a single colony to sequence and calculate the ratio of full-length gene.
The plasmid cDNA library of the liver from Microtus fortis was constructed by using SMART technology. The purposed colonies were got through screening libraries by PCR method, and their full-length cDNA sequences were obtained by sequencing with pBluescriptⅡSK universal primers M13R.
Results:
Voles fed the high-fat diet developed panlobular macrovesicular steatosis, voles fed the standard diet developed light steatosis, whereas those fed the high-fiber diet had normal livers.
Compared with the control group, liver weight and liver index of model group 1 were significantly increased (P< 0.05), serum ALT, AST, TC, FFA, r-GT, LDL, CHE and GLU were significantly high (P< 0.05), HDL and TG were significantly low (P < 0.05). Real-time PCR showed that the five genes of CYP2E1, ECHS1, CYP2D5, CYP2a3a and PGC-1 were high-expression (P< 0.05), the three genes of SC4MOL, Adipor and AMPK-1 were low-expression (P< 0.05).
Compared with control group, the liver weight and liver index of model group 2 were significantly increased (P< 0.05), the FFA, LDL and CHE also significantly increased (P< 0.05), HDL of blood decreased significantly (P< 0.05), other indexes had no significant difference. Real-time PCR showed that all the gene expression trends are not obvious (P> 0.05).
cDNA plasmid library of Microtus fortis liver was constructed by using SMART technology. The titers of this cDNA library were 1076 pfu/ul, the recombination rate was about 94%, the library capacity was 1.08×106, the integrity rate was 77.3%.
Three full-length cDNA sequences of Microtus fortis CYP2D5, CYP2E1 and ECHS1 were obtained. The CYP2D5 cDNA is 1865bp in length and contains a 1482bp open reading frame (ORF) encoding a 494 amino acids. The CYP2D5 cDNA is 1690bp in length, and contains a 1514bp ORF encoding 504 amino acids. The ECHS1 cDNA is 1013bp in length, and contains an 873bp ORF encoding 290 amino acids. Sequence analysis reveals that the identity of the three cDNA sequences and deduced amino acids among Microtus fortis, Homo saplens, Mus musculus and Rattus norvegicus is high.We have registerd the three full-length cDNA sequences in the GenBank, registration are respectively GQ507485, GQ507486, GQ845171.
非酒精性脂肪肝(nonalcoholic fatty liver disease,NAFLD)发病率逐年增高,且有进展到肝纤维化肝硬化的趋势,目前其确切的发病机制尚不清楚。我们在以往的实验中发现东方田鼠有易发脂肪肝的倾向,因此建立东方田鼠非酒精性脂肪肝模型,利用SMART (Switching Mechanism at 5'end of RNA Transcript, RNA5'端转录机制)技术构建了东方田鼠肝脏cDNA (complementary DNA,互补DNA)质粒文库,在此基础上筛选与东方田鼠脂肪肝发病相关的基因,并获得其全长序列,为进一步研究非酒精脂肪肝发病机制奠定基础。
方法：
选取105只6周龄洞庭湖种群雄性东方田鼠,随机分成三组,每组35只,分别为对照组、模型组1和模型组2,各组分别饲喂高纤维料(在大小鼠基础料的基础上加粗纤维,使粗纤维含量为10%,粗脂肪含量为3%)、高脂料(在大小鼠基础料的基础上加5%猪油、0.5%胆固醇和0.1%胆盐)、大小鼠基础料。各组分别于造模开始后第2、4、6、8、12周处死,称量体重及肝重,计算肝指数,采血检测东方田鼠血清丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、甘油三酯(TG)、总胆固醇(TC)、碱性磷酸酶(ALP)、游离脂肪酸(FFA)、血糖(GLU)、r-谷氨酰转移酶(r-GGT)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)和胆碱酯酶(CHE),并取肝脏HE染色后做病理学观察。通过文献确定,可能与非酒精性脂肪肝相关的基因,参照NCBI中大小鼠基因cDNA序列的保守区设计其特异性引物,进行实时荧光定量PCR检测,比较基因动态表达水平。
选取12月龄洞庭湖种群东方田鼠4只,取肝脏组织,提取总RNA,用SMART技术构建东方田鼠肝脏cDNA质粒文库,测定文库滴度和容量,并随机挑选单个菌落测序,计算全长基因的比率
根据实时荧光定量PCR结果确定目的基因,通过PCR方法筛选cDNA质粒文库,获得目的菌落,用pBluescriptⅡSK通用引物M13R测序,获得基因的全长序列,并进行序列分析比较。
结果：
模型组1东方田鼠肝细胞均呈现弥漫性脂肪变性,模型组2东方田鼠肝细胞脂肪变性较轻,对照组东方田鼠肝脏基本正常。
与对照组相比,模型组1肝重和肝指数都明显升高(P<0.05),血清ALT、AST、TC、FFA、r-GGT、LDL、CHE和GLU都明显升高(P<0.05),HDL和TG均明显降低(P<0.05),ALP无明显差异(P>0.05)；对8个基因进行了实时荧光定量PCR结果显示肝组织中的CYP2E1(细胞色素P4502E1)、ECHS1(烯酰辅酶A水合酶短链1)、CYP2D5(细胞色素P4502D5)、CYP2a3a(细胞色素P4502a3a)和PGC-1(过氧化物酶体增殖物激活受体辅激活因子1)这5基因表达上调(P<0.05),SC4MOL(固醇甲基氧化酶)、Adipor(脂联素受体)和AMPK-1(腺苷酸活化激酶-1)这3个基因表达下调(P<0.05)。
与对照组相比,模型组2肝重和肝指数明显升高(P<0.05),血清FFA、LDL、CHE显著升高(P<0.05),HDL明显降低(P<0.05),其余指标与对照组相比无显著差异；实时荧光定量PCR结果显示所测基因未有明显改变(P>0.05)。
利用SMART技术构建了东方田鼠肝脏cDNA质粒文库,该cDNA文库滴度为1076 pfu/μL,重组率约94%,库容量达1.08×106。测定了22个克隆序列经BLAST分析,与GenBank中大鼠、小鼠、田鼠以及人类已知功能蛋白具有75%以上的同源性,基因完整性比率为77.3%。
克隆了CYP2E1、CYP2D5、ECHS1三个基因,并获得了它们的全长cDNA序列。CYP2E1基因cDNA全长为1685bp,有1482bp的完整开放阅读框,编码494个氨基酸：CYP2D5基因cDNA全长为1690bp,有1514bp的完整开放阅读框,编码504个氨基酸；ECHS1基因cDNA全长为1013bp,有873bp的完整开放阅读框,编码290个氨基酸。这三个基因的核酸序列及其推测的氨基酸序列与人、大小鼠序列高度同源。在GenBank中注册号分别为GQ507485、GQ507486、GQ845171。
Objective:
The incidence of Non-alcoholic fatty liver (nonalcoholic fatty liver disease, NAFLD) increased year by year, and the disease can progress to liver fibrosis and cirrhosis, but its precise mechanism is currently unclear. Our early experiment showed that Microtus fortis is prone to fatty liver, therefore, the purpose of this study is to establish a Non-alcoholic fatty liver model of Microtus fortis, and to study the pathogenesis of Non-alcoholic fatty liver disease in the model of Microtus fortis.
Methods:
We selected 105 male Microtus fortis in Dongting Lake which are 6-week-old, and randomly divided them into three groups.The three groups were fed the high-fat ingredients (plus 5% lard,0.5% cholesterol and 0.1% bile salt into based on the standard diet for rats and mice, model 1 group), the standard diet (model 2 group), the high-fiber material (the final concentration of Bold fiber was 10%, crude fat was 3% on the basis of the standard diet for rats and mice, control group) respectively.7 voles of each group were sacrificed at the beginning of the study time of 2,4,6,8,12week. During the process of our study we had observed the general situation and changes in liver index of Microtus fortis. ALT, AST, TG, TC, ALP, FFA, r-GT, HDL, LDL, CHE, GLU values were measured by biochemistry analyzer. The histological changes of all voles'livers were observed using light microscopy. Genes which should be possible related to non-alcoholic fatty liver were selectecd. The cDNA-specific primers were designed in the conserved region according to the sequences of mice and rats from the NCBI. Then real-time PCR was done to obtain the gene expression levels of the livers.
We selected four Microtus fortis in Dongting Lake which are 12 months of age, after we sacrificed them whichever liver were obtained to extracte total RNA, then The plasmid cDNA library from liver of Microtus fortis was constructed by using SMART technology. The titers and capacity of this cDNA library were determined. Randomly selected a single colony to sequence and calculate the ratio of full-length gene.
The plasmid cDNA library of the liver from Microtus fortis was constructed by using SMART technology. The purposed colonies were got through screening libraries by PCR method, and their full-length cDNA sequences were obtained by sequencing with pBluescriptⅡSK universal primers M13R.
Results:
Voles fed the high-fat diet developed panlobular macrovesicular steatosis, voles fed the standard diet developed light steatosis, whereas those fed the high-fiber diet had normal livers.
Compared with the control group, liver weight and liver index of model group 1 were significantly increased (P< 0.05), serum ALT, AST, TC, FFA, r-GT, LDL, CHE and GLU were significantly high (P< 0.05), HDL and TG were significantly low (P < 0.05). Real-time PCR showed that the five genes of CYP2E1, ECHS1, CYP2D5, CYP2a3a and PGC-1 were high-expression (P< 0.05), the three genes of SC4MOL, Adipor and AMPK-1 were low-expression (P< 0.05).
Compared with control group, the liver weight and liver index of model group 2 were significantly increased (P< 0.05), the FFA, LDL and CHE also significantly increased (P< 0.05), HDL of blood decreased significantly (P< 0.05), other indexes had no significant difference. Real-time PCR showed that all the gene expression trends are not obvious (P> 0.05).
cDNA plasmid library of Microtus fortis liver was constructed by using SMART technology. The titers of this cDNA library were 1076 pfu/ul, the recombination rate was about 94%, the library capacity was 1.08×106, the integrity rate was 77.3%.
Three full-length cDNA sequences of Microtus fortis CYP2D5, CYP2E1 and ECHS1 were obtained. The CYP2D5 cDNA is 1865bp in length and contains a 1482bp open reading frame (ORF) encoding a 494 amino acids. The CYP2D5 cDNA is 1690bp in length, and contains a 1514bp ORF encoding 504 amino acids. The ECHS1 cDNA is 1013bp in length, and contains an 873bp ORF encoding 290 amino acids. Sequence analysis reveals that the identity of the three cDNA sequences and deduced amino acids among Microtus fortis, Homo saplens, Mus musculus and Rattus norvegicus is high.We have registerd the three full-length cDNA sequences in the GenBank, registration are respectively GQ507485, GQ507486, GQ845171.
引文
1. Brunt EM. Nonalcoholic steatohepatits [J]. Seminars in Liver Disease,2004,24: 3-20.
2. Greefield V, Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease [J]. Curr Opin Gastroenterol,2008,24(3):320-327.
3 Mc Cullough AJ. The clinical features, diagnosis and natural history of nonalco-holic fatty liver disease [J]. ClinLiver Dis,2004,8:521-533.
4. Browning J, Szczepaniak L, Dobbins R, etal. Prevalence of hepatic steatosis in an urban population in the Unjted States:impact of ethnicity [J]. Hpatology,2004, 40:1387-1395.
5. 南月敏,王蕾,李良霄,等,非酒精性脂肪肝动物模型研究进展[J].河北医科大学学报,2007,3,28(1)：67-71.
6. 徐磊,徐承富,石巧娟,等.小鼠非酒精性脂肪性肝病模型的建立与评价[J].中华肝脏病杂志,2007,15(9)：693-694.
7. 张瑜,李琳琳,张嫣之,等.非酒精性脂肪肝大鼠模型的建立[J].新疆中医药,2007,25(2)：7-9.
8. Lin Hz, Yang SQ, Chuckaree C, et al. Metformin's reverses fatty liver disease in obese leptin-deficient mice [J]. Nature Medicine,2000,6(8):998-1003.
9. 何永康,张新跃.东方田鼠的研究进展[J].中国实验动物学杂志,1998,8(2)：116-119.
10. Horing J, Khabarovsk virus.A genetically and serologically distincthantavirus isolated from Microtus fortis trapped in far east Russia [J]. Gen virol,1996,77: 687-69.
11. 李浩,何艳燕,林矫矫,等.东方田鼠抗日本血吸虫现象的观察[J].中国兽医寄生虫病,2000,8(2)：12-15.
12.孙军,林矫矫,程国锋,等.利用基因表达谱芯片研究东方田鼠和小鼠感染日本血吸虫前后基因的差异性表达[J].北京大学学报(自然科学版),2004,40(4)：532-536.
13. 周光兴,谢建云,柏熊,等.不同年龄东方田鼠组织器官的形态学观察[J].华东地区第十届实验动物科学学术交流会论文集,2008：395.
14. Mascitelli L, Pezzetta F.Diagnosis of nonalcoholic fatty liver disease [J]. JAMA,2003,290:1577.
15. Day CP, James OF. Steatohepatitis-a tale of two "hits" [J]. Gastroenterology, 1998,114:842-845.
16. Blechacz B, Stremmel W. NASH nonalcoholic steatohepatitis.Z Gastroentero, 2003,41(1):77-90.
17. Perez-Aguilar F. Etiopathogenesis of non-alcoholic steatohepatitis [J]. Gastroen-terol Hepatol,2005,28(7):396-406.
18. Lee O, Bruce WR, Dong Q, etal. Fructose and carbonyl metabolites as endogen-ous toxin [J]. Chem Biol Interact,2009,178(1-3):332-339.
19. Jou J, Choi SS, Diehl AM.Mechanisms of disease progression in nonalcoholic fatty liver disease [J]. Semin Liver Dis,2008,28(4):370-379.
20. Quentin M. Anstee, Robert D. Goldin. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Path.2006,87:1-16.
21. 钟岚,范建高.非酒精性脂肪肝动物模型.国外医学消化系疾病分册,1999,19(3)：175-178.
22. 杨英听,毕秀丽,朱培庭.非酒精性脂肪肝动物模型研究纂要[J].中医药学刊,2005,23(4)：647-650.
23. 张玉峰,陈文慧.非酒精性脂肪肝动物模型造模方法的研究[J].中西医结合肝病杂志,2002,13(2)：123-125.
24. 倪鸿昌,李俊,金涌,等.大鼠实验性高脂血症和高脂血症性脂肪肝模型究[J].中国药理学通报,2004,6,20(6)：703-706.
25. 钟岚,范建高,王国良,等.肥胖高脂血症性脂肪性肝炎模型的建立.实验动物科学与管理,2000,17(2)：16-20.
26. 钟岚,范建高,王国良,等.非酒精性脂肪性肝炎动物模型的建立.中华实用医学,2000,2(1)：3-6.
27. Gochee PA, Jonsson JR, Clouston ND, et al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P4502E1 [J]. J Gastroenterol Hepatol, 2003,18 (4):38-92.
28. Yeo-Pyo Y, Cassazza JP, Sohn DH, et al. Pretranslational activation of cytochr-ome P450ⅡE during ketosis induced by a high fat diet [J]. MolPharmacol, 1989,41:474-479.
29. 王彦,施雪清,王琳琳,等.饮食诱导非酒精性脂肪性肝病大鼠脂联素受体2基因的表达及其意义[J].大连医科大学学报,2008,6(30)：530-532.
30. 方诗蓉,傅玉才,周小辉,PGC-1与非酒精性脂肪肝病关系的研究进展[J].国际消化病杂志,2009,29(6)：390-392.
31. 刘蓉,鞠艳芳,杨金菊,等.烯脂酰辅酶A水解酶单克隆抗体的制备与鉴定 [J].细胞与分子免疫学杂志,2008,24(4)：387-389.
32. 黎申凯,朱祖林,金壁如,等.东方田鼠对日本血吸虫的不感染性[J].寄生虫学报,1965,2(1)：103.
33. 朱国正,汪英华,雷观愚.东方田鼠的实验室饲养及其抗血吸虫感染特性.上海实验动物科学,1991,11(4)：193-198.
34. 柏熊,刑正弘,何新桥,等.上海地区东方田鼠实验室繁育研究[J].上海实验动物科学(华东地区第六次实验动物科学学术交流会论文辑),2000,20(3)：174.
35. 俞远京,苏志杰,彭兴华,等.我国野生东方田鼠的医学实验动物化[J].中国现代医学杂志,2003,56(6)：76-79.
36. 邵伟娟,谢建云,王胜昌,等.两个不同地区东方田鼠杂交子代RAPD标记分析[J].中国实验动物学报,2001,9(2)：93-98.
37. 潘漪清,谢建云,邵伟娟,等.不同地区东方田鼠染色体数及带型比较[J].中国实验动物学杂志,2002,12(3)：131-134.
38. 谢建云,潘漪清,高诚.东方田鼠乳酸脱氢酶同工酶的研究[J].中国实验动物学报,2001,9(4)：221-223.
39. 俞远京,苏志杰,马亚东,等.诱发性东方田鼠糖尿病动物模型的初步研究[J].湖南畜牧兽医,2003,4：8-9.
40. YAN H J, HUANG X Q, CHENG Z Q. Advances of the Studies on Construc-tion Strategy and Analysis of cDNA Library [J]. Journal of Yunnan Agricultural University,2006,21(1):1-6.
41. ZHAO Zhi-Hui, LI Ning. Construction of cDNA Library and its Parameter Evaluating on EST Sequencing [J]. Journal of Agricultural Biotechnology,2003, 11(4):422-425.
42. 樊红.克隆新基因cDNA全长的策略和方法[J],国外医学遗传学分册,2002,25(1)：11-13.
43. 何东苟,余新炳,吴忠道.全长cDNA文库的构建和新基因全长cDNA克隆的策略[J].热带医学杂志,2003,3(4)：473-476.
44.龙松华,陈信波,邓欣,高原.SMART技术构建亚麻韧皮部全长cDNA文库[J].中国麻业科学,2008,30(3)：128-130.
45. Maria MH, Ravi PS, Scot H, et al. Targeted mapping of ESTs linked to the adult plant resistance gene Lr46 in wheat using synteny with rice [J]. Funct Integr Ge- nomics,2006,6:122-131.
46. 朱利军,长孙东亭,罗素兰.全长cDNA文库构建方法及应用研究[J].海南 大学学报自然科学版,2009,27(2)：185-190.
47. 邵珏,邵玉锁,曹明富,获取基因全长cDNA策略及应用[J].健康研究,2009,29(2)：140-142.
48. SPIR NKS, LJUB MOV AV, CASTELLON R, et al. Analysis of Gene express-ion in human bullous keratopathy corneas Containing limiting amounts of RNA [J]. Invest Ophthalmol Vis Sci,1999,40 (13):3110-3115.
49. 毛新国,景蕊莲,孔秀英,等.几种全长cDNA文库构建方法比较[J].遗传学,2006,28(7)：865-873.
50. ZHU Y Y, MACHLEDER EM, CHENCH IK A, et al. Reverse transcriptase template switching: a SMART approach for full length cDNA library construc-tion [J]. Biotechniques,2001,30(4):892-897.
51. WELLENREUTHER R, SCHUPP I, POUSTKA A, et al. The German cDNA Consortium. SMART amplification combined with cDNA size fractionation in order to obtain large full length clones [J]. BMC Genomics,2004,5(1):36-40.
52. 张晖,张静,田杰,等.婴幼儿小肠组织全长cDNA文库的构建及鉴定[J].中国实用儿科杂志,2008,2(23)：133-135.
53. 蔡宁波,黄湘文,庄伟建.花生种子全长cDNA文库的构建和鉴定[J].花生学报,2007,36(2)：1-5.
54.杨锡明,高 磊,栾 静,等.获取基因PGC-1与非酒精性脂肪肝病关系的研究进展全长cDNA的方法及其进展[J].现代检验医学杂志,2005,5(3)：80-83.
55. Cai Y, Gao Y, Sheng Q, el al.Characterization and potential function of a novel testis 2 specific nucleo-porin BS-63 [J]. Mol Reprod 2002,61(1):126-134.
56. Wang Ying, et al. Molecular cloning and sequence analysis of growth hormone genell of chun salmon (ONCORHYNCHUN KETA). Acta Zoologica Sinica,1 996,42(2):189-196.
57. 王关林,方宏筠.植物基因工程原理与技术[M].北京：科学出版社,1998.
58. Frohman M A, Dush M K, Martin G R. Rapid production of full-length cDNAs from rare transcripts:Amplification using a single gene-specific oligonuleotide primer[J]. Proc Natl Acad Sci USA,1988,85:8998-9002.
59. Zhang Qing-hua, Mao Yu, Chen Zhu. Strategy of Intact cDNA Cloning in Genome Study [J]. Journal of Chinese Biotechnology,2000,20(4):3-5.
60. 范建高,钟岚,吴伟清,等.非酒精性脂肪性肝炎肝细胞内细胞色P4502E1的表达[J].中国肝脏,1999,2(2)：205-206.
61. Koop DR. Oxidative and reductive metabolism by cytochromeP4502E1 [J]. FASEB,1992,6:724-730.
62. WeltmanMD, Farrell GC, Hall P, et al. Hepatic cytochrome P4502E1 is increas-ed in patients with nonalcoholic steatohepatitis [J]. Hepatolygy,1998,27: 128-133.
63. Weltman MD, Farrell GC, Liddle C, et al. Increased CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation[J].Gastroenterology, 1996,111:1645-1653.
64. Frank J G. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1 [J]. Mutation Research,2005,69:101-110.
65. 林苗,林丽香,陈刚,等.CYP2E1基因在2型糖尿病大鼠肝脏的表达[J].海峡预防医学杂志,2003,5(9)：8-10.
66. Prando ta J. Important role of prodromal viral infections responsible for inhibit-tion of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye'ssyndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and heap-totoxicity of the therapeutic doses of acetaminophem used in genetically pred-isposed persons [J]. Am J Ther,2002,9 (2):149-156.
67. Lee K S, Buck M, Houglum K, et al. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expre-ssion [J]. J Clin Invest,1995,96:2461-2468.
1. Mehta K, Van Thiel DH, Shah N, et al. Nonalcoholic fatty liver disease pathogen-nesis andthe role of antioxidants [J]. Nut r Rev,2002,60:289-293.
2. 翁小刚,朱晓新,杨庆,等.非酒精性脂肪肝的实验研究进展[J].中国实验方剂学杂志,2009,15(11)：104-109.
3. 谢雯,脂肪性肝病的研究进展[J].中国临床医生,2006,8(34)：2-24.
4. 刘树军,黄静娟,车念聪,非乙醇性脂肪肝发病机制研究进展[J].首都医科大学学报,2007,2(28)：216-219.
5. Rashid M, Robert s EA. Nonalcoholic steatohepatitis in children [J]. J Pediatr Gast roenterol Nutr,2002,30(6):48-53.
6. Day C, Janny O. Steatohepatitis:"a tale of two hits"? [J]. Gastroenterology,1998, 114:842-845.
7. 顾鸣宁,胰岛素抵抗与脂肪肝[M].国外医学.内分泌分册,2003,23(增刊)：32
8. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome [J]. Science,2001,294:2166-2170.
9. Weltman MD, Farrell GC, Liddle CI Increased hepatocyteCYP2El expression in a rat nutritional model of hepatic steatosis with inflammation [J].Gastroenter-ology,1996,111:16451.
10. ChitturiS, Farrell GC. Etio-pathogenesis of nonalcoholic-steatohepatitis [J]. Semin Liver Dis,2001,21 (1):27-41.
11. Brown MS, Goldstein J L.The SREBP pathway:Regulation of tholesterol meta-bolism by proteolysis of a membrane-bound transcription factor [J]. Cell,1997, 89(3):331-340.
12. Tarling E, Salter A, Bennett A. Transcriptional regulation of human SREBP-1c (sterol-regulatory-element-binding protein-1c):a key regulator of lipogenesis [J]. Biochem Soc Trans,2004,32(1):107-109.
13.杜饶,谢梅林,SREBPs的调节及在非酒精性脂肪肝形成机制中的研究进展[J].中国药理学通报,2009,25(11)：1412-1415.
14. Kamuta T, Lee Y, Higa M, et al. Leptin, troglitazone and the expression of sterol regulatory element binding proteins in liver and pancreatic islets [J]. Proc Natl Acad Sci USA,2000,97:8536-8541.
15. Horton J D, Goldstein J L, Brown M S, SREBPs:activators of the complete program of cholesterol and fatty acid synthesis in the liver[J]. J Clin Invest, 2002,109(9):1125-1131.
16. 王光丽,周小辉,傅玉.非酒精性脂肪性肝病和固醇调节元件结合蛋白-1c[J]肝脏,2008,13(3)：257-259.
17. Kakuma T, Lee Y, Higa M, et al. Leptin, troglitazone and the expression of sterol regulatory element binding proteins in liver and pancreatic islets [J]. Proc Nall Acad Sci USA,2000,97(15):8536-8541.
18. Muller G, Ertl J, Gerl M, et al. Leptin impairs metablic actions of insulin in isolated rat adipocytes [J]. J Biol Chem,1997,272(16):10585-10593.
19. Kamohara S, Barcelin R, Halaas JL, et al. Acute stimulation of glucose metabo-lism in mice by leptin treatment [J]. Nature,1997,389(6649):374-377.
20. 范挺,瘦素对非酒精性脂肪肝病的影响[J].内肛科技,2009,2：34-42.
21. Horton JD, Shah NA, Warrington JA, et al. Combined analysis of oligonuc-leotide microarray data from transgenic and knockout mice ideatitles direct SREBP target genes [J].Prec Natl Acad Sci USA,2003,100(21):12027-12032.
22. Berg AH, Combs TP, Du XL, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J]. NatMed,2001,7(8):947-953.
23. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice [J]. Proc NatlAcad Sci USA,2001,98(4): 2005-2010.
24. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis.The missing link of adipo-vascular axis [J]. J Biol Chem,2002, 227(40):37487-37491.
25. Yu S, Malsusue K, Kashireddy P, et al. Adipocyte-specific gene expression and adioogenic steatosis in the mouse live due to peroxisome proliferators-activated receptor γ1(PPAR γ1)overexpression [J]. J Biol Chem,2003,278:498-505.
26. Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease [J]. Eur J Endocrinol,2005,152:113.
27. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, Produc-Ed exclusively in adipocytes [J]. J Biol Chem,1995,270(45):26746-26749.
28. Shulman GI. Cellular mechanisms of insulin resistance [J]. J Clin Invest,2000, 106(2):171-176.
29. Yokota T, Oritani K, Takahashi I, ET al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelo- monocytic Progenytors and the function of macrophages [J]. Blood,2000,96: 1723-1732.
30. 刘蓉,鞠艳芳,杨金菊,等.烯脂酰辅酶A水解酶单克隆抗体的制备与鉴定[J].细胞与分子免疫学杂志,2008,24(4)：387-389.
31. 方诗蓉,傅玉,周小辉,PGC-1与非酒精性脂肪肝病关系的研究进展[J].国际消化病杂志,2009,29(6)：390-392.
32. Michael LF,Wu Z, Cheatham RB, et al. Restoration of insulin sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1 [J]. Proc Natl Acad Sci USA,2001,98:3820-3825.
33. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic glueoneogenesis through the transcriptional coactivator PGC-1 [J]. Nature,2001,413:131-138.
34. Herzig S, Hedrick S, Morantte I, et al. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma [J]. Nature,2003,426:190-193.
35. Finck BN, Kelly DP. PGC-1 coactivators:inducible regulators of energy metabolism in health and disease [J]. J Clin Invest,2006,116:615-622.
36. Koo SH, Satoh H, Herzig S, et al. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3 [J]. Nat Med,2004,10: 530-534.
37. Zhang Y, Castellani LW. Sinai CJ, et al. Peroxisome proliferator activated receptor gamma coaetivator 1a (PGC-1a) regulates triglyceride metabolism by activation of the nuclear receptor FXR [J]. Genes,2004,18:157-169.
38. Lieber CS, Alcoholic fatty liver:its pathogenesis and mechanism of progression to inflammation and fibrosis [J]. Alcohol,2004,34:9-19.
39. 范建高,钟岚,吴伟清,等.非酒精性脂肪性肝炎肝细胞内细胞色P4502E1的表达[J].肝脏,1999,2(2)：205-206.
40. Gochee PA, Jonsson JR, Clouston ND, et al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P4502E1 [J]. J Gastroenterol Hepatol, 2003,18(4):386-92.
41. Yeo-Pyo Y, Cassazza JP, Sohn DH, et al. Pretranslational activation of cytochro-me P4502E1 during ketosis induced by a high fat diet [J]. Mol Pharmacol,1989,41:474-479.
42. Gochee PA, Jonsson JR, Clouston ND, ET al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P4502E1 [J]. Gastroenterol Hepatol,2003, 18(4):386-392.
43. Koop DR. Oxidative and reductive metabolism by cytochrome P4502E1 [J]. FASEB,1992,6:724-730.
44. WeltmanMD, Farrell GC, Hall P, et al.Hepatic cytochrome P4502E1 is increa-sed in patients with nonalcoholic steatohepatitis [J]. Hepatolygy,1998,27: 128-133.
45. Weltman MD, Farrell GC, Liddle C, et al. Increased CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation [J].Gastroenterology, 1996,111:1645-1653.
46. Frank J G. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1 [J]. Mutation Research,2005,69:101-110.
47. 林 苗,林丽香,陈 刚,等.CYP2E1基因在2型糖尿病大鼠肝脏的表达[J].海峡预防医学杂志,2003,5(9)：8-10.
48. Prando ta J. Important role of prodromal viral infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepatotoxicity of the therapeutic doses of acetaminophem used in genetically predisposed persons [J]. Am J Ther,2002,9(2):149-156.
49. Lee K S, Buck M, Houglum K, et al. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb express- ion [J]. J Clin Invest,1995,96:2461-2468.
50. 历有名,夏维新.脂肪肝现代诊疗[M].江苏科学技术出版社,2003：
51.程勇,赵亚敏,苏剑,等.非酒精性脂肪性肝病患者血清IL-18、IL-8水平变化及意义[J].山东医药,2009,49(39)：70-71.
51.赵晓琴,赵明敬,非酒精性脂肪肝发病机制研究进展[J].湖北民族学院学报.医学版,2007,24(2)：67-69.
52. Medina EA, Erichson KL, Stanhope KL, et al. Evidence that tumor necrosis factor-alpha-induced hyperinsulinemia prevents decreases of circulating leptin during fasting in rat [J].Metabolism,2002,51:1104-1110.
53. 吴晓华,李莉,非酒精性脂肪性肝病的相关基因研究[J].肝脏,2005,10(4)：337-338.
54. Yang YS, Song HD, Li RY, et al. The gene expression profiling of human visceral adipose tissue and its secretory functions. Biochem Biophys Res Commun 2003,300:839-846.
55. Day CP, James of wsteatohepaltiffs:atale of two hits [J]. Gastroenterology, 1998,114:842-845.
56. 王春艳.白细胞介素18基因多态性与疾病的关系研究进展[J].检验医学与临床,2007,4(2)：104-106.
57. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene [J].Science,1995,269(5223):543-546.
58. Chehab FF, L im ME, Lu R. Correction of the sterilitv defect in homozygous obese female mice by treatment with the human recombinant Leptin [J]. Nat Genet,1996,12(3):318-320.
59. Neuschwander, Tetri BA. A resistance movement in NASH [J]. Am Gastroent-erol,2001,96 (10):2813-2814.
60. Loffreda S, Yang SQ, L in HZ, et al. Leptin regulates proin-flammatory immune responses [J]. FASEB J,1998,12(1):57-65.
2. Greefield V, Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease [J]. Curr Opin Gastroenterol,2008,24(3):320-327.
3 Mc Cullough AJ. The clinical features, diagnosis and natural history of nonalco-holic fatty liver disease [J]. ClinLiver Dis,2004,8:521-533.
4. Browning J, Szczepaniak L, Dobbins R, etal. Prevalence of hepatic steatosis in an urban population in the Unjted States:impact of ethnicity [J]. Hpatology,2004, 40:1387-1395.
5. 南月敏,王蕾,李良霄,等,非酒精性脂肪肝动物模型研究进展[J].河北医科大学学报,2007,3,28(1)：67-71.
6. 徐磊,徐承富,石巧娟,等.小鼠非酒精性脂肪性肝病模型的建立与评价[J].中华肝脏病杂志,2007,15(9)：693-694.
7. 张瑜,李琳琳,张嫣之,等.非酒精性脂肪肝大鼠模型的建立[J].新疆中医药,2007,25(2)：7-9.
8. Lin Hz, Yang SQ, Chuckaree C, et al. Metformin's reverses fatty liver disease in obese leptin-deficient mice [J]. Nature Medicine,2000,6(8):998-1003.
9. 何永康,张新跃.东方田鼠的研究进展[J].中国实验动物学杂志,1998,8(2)：116-119.
10. Horing J, Khabarovsk virus.A genetically and serologically distincthantavirus isolated from Microtus fortis trapped in far east Russia [J]. Gen virol,1996,77: 687-69.
11. 李浩,何艳燕,林矫矫,等.东方田鼠抗日本血吸虫现象的观察[J].中国兽医寄生虫病,2000,8(2)：12-15.
12.孙军,林矫矫,程国锋,等.利用基因表达谱芯片研究东方田鼠和小鼠感染日本血吸虫前后基因的差异性表达[J].北京大学学报(自然科学版),2004,40(4)：532-536.
13. 周光兴,谢建云,柏熊,等.不同年龄东方田鼠组织器官的形态学观察[J].华东地区第十届实验动物科学学术交流会论文集,2008：395.
14. Mascitelli L, Pezzetta F.Diagnosis of nonalcoholic fatty liver disease [J]. JAMA,2003,290:1577.
15. Day CP, James OF. Steatohepatitis-a tale of two "hits" [J]. Gastroenterology, 1998,114:842-845.
16. Blechacz B, Stremmel W. NASH nonalcoholic steatohepatitis.Z Gastroentero, 2003,41(1):77-90.
17. Perez-Aguilar F. Etiopathogenesis of non-alcoholic steatohepatitis [J]. Gastroen-terol Hepatol,2005,28(7):396-406.
18. Lee O, Bruce WR, Dong Q, etal. Fructose and carbonyl metabolites as endogen-ous toxin [J]. Chem Biol Interact,2009,178(1-3):332-339.
19. Jou J, Choi SS, Diehl AM.Mechanisms of disease progression in nonalcoholic fatty liver disease [J]. Semin Liver Dis,2008,28(4):370-379.
20. Quentin M. Anstee, Robert D. Goldin. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Path.2006,87:1-16.
21. 钟岚,范建高.非酒精性脂肪肝动物模型.国外医学消化系疾病分册,1999,19(3)：175-178.
22. 杨英听,毕秀丽,朱培庭.非酒精性脂肪肝动物模型研究纂要[J].中医药学刊,2005,23(4)：647-650.
23. 张玉峰,陈文慧.非酒精性脂肪肝动物模型造模方法的研究[J].中西医结合肝病杂志,2002,13(2)：123-125.
24. 倪鸿昌,李俊,金涌,等.大鼠实验性高脂血症和高脂血症性脂肪肝模型究[J].中国药理学通报,2004,6,20(6)：703-706.
25. 钟岚,范建高,王国良,等.肥胖高脂血症性脂肪性肝炎模型的建立.实验动物科学与管理,2000,17(2)：16-20.
26. 钟岚,范建高,王国良,等.非酒精性脂肪性肝炎动物模型的建立.中华实用医学,2000,2(1)：3-6.
27. Gochee PA, Jonsson JR, Clouston ND, et al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P4502E1 [J]. J Gastroenterol Hepatol, 2003,18 (4):38-92.
28. Yeo-Pyo Y, Cassazza JP, Sohn DH, et al. Pretranslational activation of cytochr-ome P450ⅡE during ketosis induced by a high fat diet [J]. MolPharmacol, 1989,41:474-479.
29. 王彦,施雪清,王琳琳,等.饮食诱导非酒精性脂肪性肝病大鼠脂联素受体2基因的表达及其意义[J].大连医科大学学报,2008,6(30)：530-532.
30. 方诗蓉,傅玉才,周小辉,PGC-1与非酒精性脂肪肝病关系的研究进展[J].国际消化病杂志,2009,29(6)：390-392.
31. 刘蓉,鞠艳芳,杨金菊,等.烯脂酰辅酶A水解酶单克隆抗体的制备与鉴定 [J].细胞与分子免疫学杂志,2008,24(4)：387-389.
32. 黎申凯,朱祖林,金壁如,等.东方田鼠对日本血吸虫的不感染性[J].寄生虫学报,1965,2(1)：103.
33. 朱国正,汪英华,雷观愚.东方田鼠的实验室饲养及其抗血吸虫感染特性.上海实验动物科学,1991,11(4)：193-198.
34. 柏熊,刑正弘,何新桥,等.上海地区东方田鼠实验室繁育研究[J].上海实验动物科学(华东地区第六次实验动物科学学术交流会论文辑),2000,20(3)：174.
35. 俞远京,苏志杰,彭兴华,等.我国野生东方田鼠的医学实验动物化[J].中国现代医学杂志,2003,56(6)：76-79.
36. 邵伟娟,谢建云,王胜昌,等.两个不同地区东方田鼠杂交子代RAPD标记分析[J].中国实验动物学报,2001,9(2)：93-98.
37. 潘漪清,谢建云,邵伟娟,等.不同地区东方田鼠染色体数及带型比较[J].中国实验动物学杂志,2002,12(3)：131-134.
38. 谢建云,潘漪清,高诚.东方田鼠乳酸脱氢酶同工酶的研究[J].中国实验动物学报,2001,9(4)：221-223.
39. 俞远京,苏志杰,马亚东,等.诱发性东方田鼠糖尿病动物模型的初步研究[J].湖南畜牧兽医,2003,4：8-9.
40. YAN H J, HUANG X Q, CHENG Z Q. Advances of the Studies on Construc-tion Strategy and Analysis of cDNA Library [J]. Journal of Yunnan Agricultural University,2006,21(1):1-6.
41. ZHAO Zhi-Hui, LI Ning. Construction of cDNA Library and its Parameter Evaluating on EST Sequencing [J]. Journal of Agricultural Biotechnology,2003, 11(4):422-425.
42. 樊红.克隆新基因cDNA全长的策略和方法[J],国外医学遗传学分册,2002,25(1)：11-13.
43. 何东苟,余新炳,吴忠道.全长cDNA文库的构建和新基因全长cDNA克隆的策略[J].热带医学杂志,2003,3(4)：473-476.
44.龙松华,陈信波,邓欣,高原.SMART技术构建亚麻韧皮部全长cDNA文库[J].中国麻业科学,2008,30(3)：128-130.
45. Maria MH, Ravi PS, Scot H, et al. Targeted mapping of ESTs linked to the adult plant resistance gene Lr46 in wheat using synteny with rice [J]. Funct Integr Ge- nomics,2006,6:122-131.
46. 朱利军,长孙东亭,罗素兰.全长cDNA文库构建方法及应用研究[J].海南 大学学报自然科学版,2009,27(2)：185-190.
47. 邵珏,邵玉锁,曹明富,获取基因全长cDNA策略及应用[J].健康研究,2009,29(2)：140-142.
48. SPIR NKS, LJUB MOV AV, CASTELLON R, et al. Analysis of Gene express-ion in human bullous keratopathy corneas Containing limiting amounts of RNA [J]. Invest Ophthalmol Vis Sci,1999,40 (13):3110-3115.
49. 毛新国,景蕊莲,孔秀英,等.几种全长cDNA文库构建方法比较[J].遗传学,2006,28(7)：865-873.
50. ZHU Y Y, MACHLEDER EM, CHENCH IK A, et al. Reverse transcriptase template switching: a SMART approach for full length cDNA library construc-tion [J]. Biotechniques,2001,30(4):892-897.
51. WELLENREUTHER R, SCHUPP I, POUSTKA A, et al. The German cDNA Consortium. SMART amplification combined with cDNA size fractionation in order to obtain large full length clones [J]. BMC Genomics,2004,5(1):36-40.
52. 张晖,张静,田杰,等.婴幼儿小肠组织全长cDNA文库的构建及鉴定[J].中国实用儿科杂志,2008,2(23)：133-135.
53. 蔡宁波,黄湘文,庄伟建.花生种子全长cDNA文库的构建和鉴定[J].花生学报,2007,36(2)：1-5.
54.杨锡明,高 磊,栾 静,等.获取基因PGC-1与非酒精性脂肪肝病关系的研究进展全长cDNA的方法及其进展[J].现代检验医学杂志,2005,5(3)：80-83.
55. Cai Y, Gao Y, Sheng Q, el al.Characterization and potential function of a novel testis 2 specific nucleo-porin BS-63 [J]. Mol Reprod 2002,61(1):126-134.
56. Wang Ying, et al. Molecular cloning and sequence analysis of growth hormone genell of chun salmon (ONCORHYNCHUN KETA). Acta Zoologica Sinica,1 996,42(2):189-196.
57. 王关林,方宏筠.植物基因工程原理与技术[M].北京：科学出版社,1998.
58. Frohman M A, Dush M K, Martin G R. Rapid production of full-length cDNAs from rare transcripts:Amplification using a single gene-specific oligonuleotide primer[J]. Proc Natl Acad Sci USA,1988,85:8998-9002.
59. Zhang Qing-hua, Mao Yu, Chen Zhu. Strategy of Intact cDNA Cloning in Genome Study [J]. Journal of Chinese Biotechnology,2000,20(4):3-5.
60. 范建高,钟岚,吴伟清,等.非酒精性脂肪性肝炎肝细胞内细胞色P4502E1的表达[J].中国肝脏,1999,2(2)：205-206.
61. Koop DR. Oxidative and reductive metabolism by cytochromeP4502E1 [J]. FASEB,1992,6:724-730.
62. WeltmanMD, Farrell GC, Hall P, et al. Hepatic cytochrome P4502E1 is increas-ed in patients with nonalcoholic steatohepatitis [J]. Hepatolygy,1998,27: 128-133.
63. Weltman MD, Farrell GC, Liddle C, et al. Increased CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation[J].Gastroenterology, 1996,111:1645-1653.
64. Frank J G. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1 [J]. Mutation Research,2005,69:101-110.
65. 林苗,林丽香,陈刚,等.CYP2E1基因在2型糖尿病大鼠肝脏的表达[J].海峡预防医学杂志,2003,5(9)：8-10.
66. Prando ta J. Important role of prodromal viral infections responsible for inhibit-tion of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye'ssyndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and heap-totoxicity of the therapeutic doses of acetaminophem used in genetically pred-isposed persons [J]. Am J Ther,2002,9 (2):149-156.
67. Lee K S, Buck M, Houglum K, et al. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expre-ssion [J]. J Clin Invest,1995,96:2461-2468.
1. Mehta K, Van Thiel DH, Shah N, et al. Nonalcoholic fatty liver disease pathogen-nesis andthe role of antioxidants [J]. Nut r Rev,2002,60:289-293.
2. 翁小刚,朱晓新,杨庆,等.非酒精性脂肪肝的实验研究进展[J].中国实验方剂学杂志,2009,15(11)：104-109.
3. 谢雯,脂肪性肝病的研究进展[J].中国临床医生,2006,8(34)：2-24.
4. 刘树军,黄静娟,车念聪,非乙醇性脂肪肝发病机制研究进展[J].首都医科大学学报,2007,2(28)：216-219.
5. Rashid M, Robert s EA. Nonalcoholic steatohepatitis in children [J]. J Pediatr Gast roenterol Nutr,2002,30(6):48-53.
6. Day C, Janny O. Steatohepatitis:"a tale of two hits"? [J]. Gastroenterology,1998, 114:842-845.
7. 顾鸣宁,胰岛素抵抗与脂肪肝[M].国外医学.内分泌分册,2003,23(增刊)：32
8. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome [J]. Science,2001,294:2166-2170.
9. Weltman MD, Farrell GC, Liddle CI Increased hepatocyteCYP2El expression in a rat nutritional model of hepatic steatosis with inflammation [J].Gastroenter-ology,1996,111:16451.
10. ChitturiS, Farrell GC. Etio-pathogenesis of nonalcoholic-steatohepatitis [J]. Semin Liver Dis,2001,21 (1):27-41.
11. Brown MS, Goldstein J L.The SREBP pathway:Regulation of tholesterol meta-bolism by proteolysis of a membrane-bound transcription factor [J]. Cell,1997, 89(3):331-340.
12. Tarling E, Salter A, Bennett A. Transcriptional regulation of human SREBP-1c (sterol-regulatory-element-binding protein-1c):a key regulator of lipogenesis [J]. Biochem Soc Trans,2004,32(1):107-109.
13.杜饶,谢梅林,SREBPs的调节及在非酒精性脂肪肝形成机制中的研究进展[J].中国药理学通报,2009,25(11)：1412-1415.
14. Kamuta T, Lee Y, Higa M, et al. Leptin, troglitazone and the expression of sterol regulatory element binding proteins in liver and pancreatic islets [J]. Proc Natl Acad Sci USA,2000,97:8536-8541.
15. Horton J D, Goldstein J L, Brown M S, SREBPs:activators of the complete program of cholesterol and fatty acid synthesis in the liver[J]. J Clin Invest, 2002,109(9):1125-1131.
16. 王光丽,周小辉,傅玉.非酒精性脂肪性肝病和固醇调节元件结合蛋白-1c[J]肝脏,2008,13(3)：257-259.
17. Kakuma T, Lee Y, Higa M, et al. Leptin, troglitazone and the expression of sterol regulatory element binding proteins in liver and pancreatic islets [J]. Proc Nall Acad Sci USA,2000,97(15):8536-8541.
18. Muller G, Ertl J, Gerl M, et al. Leptin impairs metablic actions of insulin in isolated rat adipocytes [J]. J Biol Chem,1997,272(16):10585-10593.
19. Kamohara S, Barcelin R, Halaas JL, et al. Acute stimulation of glucose metabo-lism in mice by leptin treatment [J]. Nature,1997,389(6649):374-377.
20. 范挺,瘦素对非酒精性脂肪肝病的影响[J].内肛科技,2009,2：34-42.
21. Horton JD, Shah NA, Warrington JA, et al. Combined analysis of oligonuc-leotide microarray data from transgenic and knockout mice ideatitles direct SREBP target genes [J].Prec Natl Acad Sci USA,2003,100(21):12027-12032.
22. Berg AH, Combs TP, Du XL, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J]. NatMed,2001,7(8):947-953.
23. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice [J]. Proc NatlAcad Sci USA,2001,98(4): 2005-2010.
24. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis.The missing link of adipo-vascular axis [J]. J Biol Chem,2002, 227(40):37487-37491.
25. Yu S, Malsusue K, Kashireddy P, et al. Adipocyte-specific gene expression and adioogenic steatosis in the mouse live due to peroxisome proliferators-activated receptor γ1(PPAR γ1)overexpression [J]. J Biol Chem,2003,278:498-505.
26. Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease [J]. Eur J Endocrinol,2005,152:113.
27. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, Produc-Ed exclusively in adipocytes [J]. J Biol Chem,1995,270(45):26746-26749.
28. Shulman GI. Cellular mechanisms of insulin resistance [J]. J Clin Invest,2000, 106(2):171-176.
29. Yokota T, Oritani K, Takahashi I, ET al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelo- monocytic Progenytors and the function of macrophages [J]. Blood,2000,96: 1723-1732.
30. 刘蓉,鞠艳芳,杨金菊,等.烯脂酰辅酶A水解酶单克隆抗体的制备与鉴定[J].细胞与分子免疫学杂志,2008,24(4)：387-389.
31. 方诗蓉,傅玉,周小辉,PGC-1与非酒精性脂肪肝病关系的研究进展[J].国际消化病杂志,2009,29(6)：390-392.
32. Michael LF,Wu Z, Cheatham RB, et al. Restoration of insulin sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1 [J]. Proc Natl Acad Sci USA,2001,98:3820-3825.
33. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic glueoneogenesis through the transcriptional coactivator PGC-1 [J]. Nature,2001,413:131-138.
34. Herzig S, Hedrick S, Morantte I, et al. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma [J]. Nature,2003,426:190-193.
35. Finck BN, Kelly DP. PGC-1 coactivators:inducible regulators of energy metabolism in health and disease [J]. J Clin Invest,2006,116:615-622.
36. Koo SH, Satoh H, Herzig S, et al. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3 [J]. Nat Med,2004,10: 530-534.
37. Zhang Y, Castellani LW. Sinai CJ, et al. Peroxisome proliferator activated receptor gamma coaetivator 1a (PGC-1a) regulates triglyceride metabolism by activation of the nuclear receptor FXR [J]. Genes,2004,18:157-169.
38. Lieber CS, Alcoholic fatty liver:its pathogenesis and mechanism of progression to inflammation and fibrosis [J]. Alcohol,2004,34:9-19.
39. 范建高,钟岚,吴伟清,等.非酒精性脂肪性肝炎肝细胞内细胞色P4502E1的表达[J].肝脏,1999,2(2)：205-206.
40. Gochee PA, Jonsson JR, Clouston ND, et al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P4502E1 [J]. J Gastroenterol Hepatol, 2003,18(4):386-92.
41. Yeo-Pyo Y, Cassazza JP, Sohn DH, et al. Pretranslational activation of cytochro-me P4502E1 during ketosis induced by a high fat diet [J]. Mol Pharmacol,1989,41:474-479.
42. Gochee PA, Jonsson JR, Clouston ND, ET al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P4502E1 [J]. Gastroenterol Hepatol,2003, 18(4):386-392.
43. Koop DR. Oxidative and reductive metabolism by cytochrome P4502E1 [J]. FASEB,1992,6:724-730.
44. WeltmanMD, Farrell GC, Hall P, et al.Hepatic cytochrome P4502E1 is increa-sed in patients with nonalcoholic steatohepatitis [J]. Hepatolygy,1998,27: 128-133.
45. Weltman MD, Farrell GC, Liddle C, et al. Increased CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation [J].Gastroenterology, 1996,111:1645-1653.
46. Frank J G. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1 [J]. Mutation Research,2005,69:101-110.
47. 林 苗,林丽香,陈 刚,等.CYP2E1基因在2型糖尿病大鼠肝脏的表达[J].海峡预防医学杂志,2003,5(9)：8-10.
48. Prando ta J. Important role of prodromal viral infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepatotoxicity of the therapeutic doses of acetaminophem used in genetically predisposed persons [J]. Am J Ther,2002,9(2):149-156.
49. Lee K S, Buck M, Houglum K, et al. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb express- ion [J]. J Clin Invest,1995,96:2461-2468.
50. 历有名,夏维新.脂肪肝现代诊疗[M].江苏科学技术出版社,2003：
51.程勇,赵亚敏,苏剑,等.非酒精性脂肪性肝病患者血清IL-18、IL-8水平变化及意义[J].山东医药,2009,49(39)：70-71.
51.赵晓琴,赵明敬,非酒精性脂肪肝发病机制研究进展[J].湖北民族学院学报.医学版,2007,24(2)：67-69.
52. Medina EA, Erichson KL, Stanhope KL, et al. Evidence that tumor necrosis factor-alpha-induced hyperinsulinemia prevents decreases of circulating leptin during fasting in rat [J].Metabolism,2002,51:1104-1110.
53. 吴晓华,李莉,非酒精性脂肪性肝病的相关基因研究[J].肝脏,2005,10(4)：337-338.
54. Yang YS, Song HD, Li RY, et al. The gene expression profiling of human visceral adipose tissue and its secretory functions. Biochem Biophys Res Commun 2003,300:839-846.
55. Day CP, James of wsteatohepaltiffs:atale of two hits [J]. Gastroenterology, 1998,114:842-845.
56. 王春艳.白细胞介素18基因多态性与疾病的关系研究进展[J].检验医学与临床,2007,4(2)：104-106.
57. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene [J].Science,1995,269(5223):543-546.
58. Chehab FF, L im ME, Lu R. Correction of the sterilitv defect in homozygous obese female mice by treatment with the human recombinant Leptin [J]. Nat Genet,1996,12(3):318-320.
59. Neuschwander, Tetri BA. A resistance movement in NASH [J]. Am Gastroent-erol,2001,96 (10):2813-2814.
60. Loffreda S, Yang SQ, L in HZ, et al. Leptin regulates proin-flammatory immune responses [J]. FASEB J,1998,12(1):57-65.